Novartis, Sudair Pharma to produce cancer drugs in KSA

Dr. Othman Fahad Al-Mutlaq, general manager of Novartis, and Dr. Yasser Ibrahim Al-Obaida, CEO of Sudair Pharmaceuticals Company, at the signing ceremony.
Updated 30 April 2019

Novartis, Sudair Pharma to produce cancer drugs in KSA

Novartis International AG and Sudair Pharmaceuticals Company (Sudair Pharma) have signed a memorandum of understanding to collaborate on local manufacturing of a range of cancer drugs in the Kingdom.

The agreement was signed under the patronage of Dr. Hisham Al-Jedaie, president of Saudi Food and Drug Authority, and in the presence of Ibrahim Saleh Al-Suwail, deputy governor of Saudi Arabian General Investment Authority (SAGIA), and Swiss Ambassador to Saudi Arabia Dr. Andreas Schaller. A number of specialists and decision-makers from the health care sector also attended the signing ceremony.

Under the agreement, Novartis will provide all technological knowhow and information on quality standards related to the production of cancer drugs to Sudair Pharma.

“Novartis, as one of the leading international pharmaceutical companies, is keen to engage with Saudi society and work with different governmental agencies to participate in the realization of the National Transformation Program (NTP) 2020 and the Saudi Vision 2030. 

“Therefore, Novartis has decided to strategically drive a long-term localization plan, which includes the transfer of technology, co-manufacturing agreements with local pharma manufacturers, building capacities and strengthening its clinical research programs.”

The Swiss pharmaceutical giant said it aims to help more Saudi patients suffering from cancer and has therefore, entered into a strategic partnership with a well-known cancer drugs manufacturing expert — Sudair Pharma. 

More than a decade ago, Novartis AG was the first company to form a dedicated global business unit to develop and launch innovative oncology medicines. 

The company focuses on five key cancer areas — breast cancer, lung cancer, melanoma, kidney cancer and hematology.

For more than 25 years, Novartis has been at the forefront of driving scientific advancements and improving clinical practice in collaboration with the global breast cancer community. 

The drugmaker also has a strong heritage in the research, development and discovery of treatments for advanced renal cell carcinoma (RCC). RCC is the most common type of kidney cancer, accounting for 90 percent of all kidney tumors. 

Established in 2014, Sudair Pharma is a Saudi-based company, which builds and operates an advanced pharmaceutical manufacturing complex to combat chronic and life-threatening diseases.

Data from the World Health Organization reveals a faster increase of cancer incidence rates in the Middle East in comparison to the rest of the world. The Saudi Cancer Registry has recorded an increase of more than 12 percent per annum compared to the global rise, which does not exceed 3 percent per annum. This acceleration is not proportional to an increase in the number of cancer treatment centers or specialized manufacturers for the production of treatment drugs.


Hyundai launches new i30 N in South Africa

Updated 19 February 2020

Hyundai launches new i30 N in South Africa

Hyundai Motors has increased its presence in South Africa by launching its first mass-produced high-performance car — i30 N — last week in Cape Town. 

The first model of the N brand, the i30 N is Hyundai’s first high-performance car, which has been developed with a key focus on its race-track capability and its ability to be a fun-to-drive everyday sports car. 

“Advanced technology and a high level of driver customization has been built into the i30 N, which means it can play the role of a comfort-oriented commuter as well as a race-track ready performance car,” the automaker said.

The i30 N has a 1,998 cc, four-cylinder turbocharged petrol engine, with its maximum power output of 202 kW reached at 6,000 r/minute, while maximum torque is achieved from 1,500 to 4 700 r/minute. 

The power is delivered to the front wheels of the i30 N through a six-speed manual gearbox and has five different drive modes: Eco, Normal, Sport, N and N Custom, which can be accessed through two dedicated buttons on the car’s steering wheel. 

The i30 N has a rev matching function built-in to adjust the engine revolutions when the driver shifts from a higher to a lower gear, thereby ensuring smooth gear shifting. The dual muffler exhaust sounds add to the pleasure of commanding a high-performance vehicle.

Speaking at the launch, Niall Lynch, CEO of Hyundai Automotive South, said: “The i30 N is one of the most exciting cars Hyundai has made in the recent years highlighting Hyundai’s talented designers and engineers who are always setting new standards.

“It is a high-performance car meant to deliver a fun driving experience and I have no doubt there’s a bright future in store for the Hyundai i30 N in South Africa. It has already been described as a ‘game changer’ with more than 20,000 units sold across Europe since we started trading in 2017.”

The i30 N has stylish 19-inch wheels with 235/35R19 Pirelli P-Zero high-performance tires and red brake callipers featuring the N-logo. Aggressive bumpers with larger air intakes and a red character line, an aerodynamic rear spoiler with a triangular brake light, and a dual muffler exhaust complete the sleek, sporty look.

The i30 N also features the electronically controlled suspension (ECS) and electronically controlled limited-slip differential, which ensures an exhilarating drive with cornering capabilities that befits the i30 N’s hot-hatch character.

Customers can choose from five color options — Polar White, Performance Blue, Micron Grey, Phantom Black and Engine Red.

Hyundai plans to launch the i30 N model in the Middle East toward the end of 2020.